Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys

View ORCID ProfileSiyu Chen, Jennifer A Flegg, Lisa J White, Ricardo Aguas
doi: https://doi.org/10.1101/2021.01.08.21249432
Siyu Chen
1Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Siyu Chen
Jennifer A Flegg
2School of Mathematics and Statistics, University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa J White
1Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Aguas
3Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ricardo@tropmedres.ac
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Accurate knowledge of levels of prior population exposure will inform preparedness plans for subsequent SARS-CoV-2 epidemic waves and vaccination strategies. Serological studies can be used to estimate levels of past exposure and thus position populations in their epidemic timeline. To circumvent biases introduced by decaying antibody titers over time, population exposure estimation methods should account for seroreversion. Here, we present a new method that combines multiple datasets (serology, mortality, and virus positivity ratios) to estimate seroreversion time and infection fatality ratios and simultaneously infer population exposure levels. The results indicate that the average time to seroreversion is five months, meaning that true exposure may be more than double the current seroprevalence levels reported for several regions of England.

Summary SARS-CoV-2 exposure in England could be double the reported seroprevalence, with implications for the impact of vaccines/other interventions.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

JF acknowledges receives funding from the Australian Research Council (DP200100747). LJW is funded by the Li Ka Shing Foundation, and the University of Oxford's COVID-19 Research Response Fund (BRD00230). RA is funded by the Bill and Melinda Gates Foundation (OPP1193472).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data, code, and materials used in the analyses can be accessed at:https://github.com/SiyuChenOxf/COVID19SeroModel/tree/master

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 09, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys
Siyu Chen, Jennifer A Flegg, Lisa J White, Ricardo Aguas
medRxiv 2021.01.08.21249432; doi: https://doi.org/10.1101/2021.01.08.21249432
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys
Siyu Chen, Jennifer A Flegg, Lisa J White, Ricardo Aguas
medRxiv 2021.01.08.21249432; doi: https://doi.org/10.1101/2021.01.08.21249432

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (163)
  • Allergy and Immunology (416)
  • Anesthesia (92)
  • Cardiovascular Medicine (865)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (397)
  • Epidemiology (8587)
  • Forensic Medicine (4)
  • Gastroenterology (390)
  • Genetic and Genomic Medicine (1766)
  • Geriatric Medicine (168)
  • Health Economics (373)
  • Health Informatics (1250)
  • Health Policy (624)
  • Health Systems and Quality Improvement (470)
  • Hematology (197)
  • HIV/AIDS (379)
  • Infectious Diseases (except HIV/AIDS) (10333)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1691)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (254)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (255)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1782)
  • Public and Global Health (3863)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (322)
  • Respiratory Medicine (522)
  • Rheumatology (208)
  • Sexual and Reproductive Health (170)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)